Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
PLoS One. 2006 Dec 20; 1:e89.Plos

Abstract

BACKGROUND

Limited information exists on long-term prognosis of patients with sustained virologic response to antiretroviral therapy. We aimed to assess predictors of unfavorable clinical outcome in patients who maintain viral suppression with HAART.

METHODS

Using data collected from ten clinic-based cohorts in Spain, we selected all antiretroviral-naive adults who initiated HAART and maintained plasma HIV-1 RNA levels <500 copies/mL throughout follow-up. Factors associated with disease progression were determined by Cox proportional-hazards models.

RESULTS

Of 2,613 patients who started HAART, 757 fulfilled the inclusion criteria. 61% of them initiated a protease inhibitor-based HAART regimen, 29.7% a nonnucleoside reverse-transcriptase inhibitor-based regimen, and 7.8% a triple-nucleoside regimen. During 2,556 person-years of follow-up, 22 (2.9%) patients died (mortality rate 0.86 per 100 person-years), and 40 (5.3%) died or developed a new AIDS-defining event. The most common causes of death were neoplasias and liver failure. Mortality was independently associated with a CD4-T cell response <50 cells/L after 12 months of HAART (adjusted hazard ratio [AHR], 4.26 [95% confidence interval {CI}, 1.68-10.83]; P = .002), and age at initiation of HAART (AHR, 1.06 per year; 95% CI, 1.02-1.09; P = .001). Initial antiretroviral regimen chosen was not associated with different risk of clinical progression.

CONCLUSIONS

Patients with sustained virologic response on HAART have a low mortality rate over time. Long-term outcome of these patients is driven by immunologic response at the end of the first year of therapy and age at the time of HAART initiation, but not by the initial antiretroviral regimen selected.

Links

Publisher Full Text
ncbi.nlm.nih.gov
dx.plos.org
PMC Free PDF

Authors+Show Affiliations

Gutierrez F
Unidad de Enfermedades Infecciosas, Hospital General Universitario de Elche, Universidad Miguel Hernández, Alicante, Spain. gutierrez_fel@gva.es
Padilla S
No affiliation info available
Masiá M
No affiliation info available
Iribarren JA
No affiliation info available
Moreno S
No affiliation info available
Viciana P
No affiliation info available
Muñoz L
No affiliation info available
Gómez Sirvent JL
No affiliation info available
Vidal F
No affiliation info available
López-Aldeguer J
No affiliation info available
Blanco JR
No affiliation info available
Leal M
No affiliation info available
Rodríguez-Arenas MA
No affiliation info available
Perez Hoyos S
No affiliation info available
CoRIS-MD
No affiliation info available

MeSH

AdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansKaplan-Meier EstimateMalePrognosisProportional Hazards ModelsRNA, ViralSpainTreatment Outcome

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17183720